Remove category matts-take
article thumbnail

Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2

pharmaphorum

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. In its third-quarter update, the Danish drugmaker reported sales of Rybelsus reached DKK 7.25

article thumbnail

Recent 340B Legislative Activity a Harbinger?

Omnicell

Matt Rosendale (R-Mont.) ” Unlike some of the other recent legislation targeting 340B entities, this bill would apply to all 340B provider categories, not just hospitals. Just a few weeks later, Rep. introduced a bill on October 5 to impose a number of new conditions on hospital eligibility in the 340B program.